Digital Genome Market Analysis

Digital Genome Market Analysis

The digital genome market by product is segmented into sequencing & analyzer instruments, DNA/RNA analysis kits, sequencing chips, sequencing & analysis software and sample preparation instruments segment. The sequencing & analyzer software segment accounted for over 12% of the market share in 2018. Technological upgrades in software packages for fabrication and evaluation of genomic sequence data will drive segmental progress. Also, a large amount of software tools that are in the developmental stage will positively impact the global market expansion over the forecast timeframe. Thus, increasing venture capital and grant for biotech research will propel sequencing & analyzer software demand over the coming years.
 

Based on application, digital genome market is sectored into microbiology, reproductive & genetic, transplantation, livestock and agriculture, forensics and research and development. The microbiology segment is further segregated into biological, clinical and industrial segments. Research and development led digital genome market will surpass USD 25 billion by 2025. Growing number of public and private investments and surge in research grants should drive industry expansion. For instance, National institute of Health (NIH) is the is the prominent public fund provider, spending around USD 40 billion per year for ongoing biomedical research for Americans. NIH funded research has led to breakthroughs such as using next-generation DNA sequencing to map landscape of the cancer genome & discover new changes linked to disease. This innovation led to growth of digital genome industry.
 

On the basis of end-use, digital genomics segmented into diagnostics & forensic labs, academic research institutes, hospitals and bio-pharmaceutical companies. Academic research institutes accounted for significant revenue share in digital genome market in 2018. This segment is experiencing high growth owing to widespread application of genome sequencing techniques for advancement of targeted drug treatments. For instance, National Human Genome Research Institute (NHGRI) collaborates with the National Institute of Cancer (NIC), to enhance genomic advances through the initiatives such as Cancer Genome Characterization Initiative (CGCI) & The Cancer Genome Atlas (TCGA). NHGRI has designed Clinical Genomic Database (CGD) of disease conditions with known genetic causes, aiming on pathologically substantial genetic data with accessible interventions.
 

Europe digital genome industry was valued over USD 6.8 billion in 2018 and is estimated to exhibit healthy growth owing to presence of numerous market players racing to seize maximum business share. In Europe, Russia digital genomics is estimated to expand at 11.4% CAGR from 2019 to 2025. The development of “Genome Russia” project is a classic example of Russia’s contribution to progression of digital genome market. The main aim of this project was to create an open access web-based database of medically relevant genomic variants characteristic to Russian population (about 3000 men & women).It also helped to identify the features that affect proliferation of diseases that would eventually lead to development of future personalized medication.
 

The U.S. digital genomics is anticipated to register significant growth during projected period. The well-established healthcare infrastructure, discovery of new genome sequencing technologies and increasing geriatric population will contribute towards revenue growth. Constant innovation, high-end technology, acquisitions and novel product launches in the U.S. has positively impacted the overall market growth. For instance, in 2017, Becton, Dickinson and Company, proclaimed the launch of BD Rhapsody, specifically designed for single cell analysis with the capacity to detect rare molecules accountable for genetic diversity that is frequently lost through whole transcriptome profiling. This launch helped to lower testing time and reduce gene sequencing prices.